

DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against *Mycobacterium tuberculosis* by T cell activation

Shigeto Yoshida^{a,**}, Takao Tanaka^b, Yoko Kita^b, Sachiko Kuwayama^b, Noriko Kanamaru^b, Yumiko Muraki^b, Satomi Hashimoto^b, Yoshikazu Inoue^b, Mitsunori Sakatani^b, Eiji Kobayashi^c, Yasufumi Kaneda^d, Masaji Okada^{b,*}

^a Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, Tochigi 329-0498, Japan

^b Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka 591-8555, Japan

^c Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Tochigi 329-0498, Japan

^d Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan

Received 11 January 2005; received in revised form 24 August 2005; accepted 25 August 2005

Available online 19 September 2005

Abstract

We investigated the immunogenicity and protective efficacy of DNA vaccine combinations expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) using gene gun bombardment and the hemagglutinating virus of Japan (HVJ)-liposome method. A mouse IL-12 expression vector (mIL-12 DNA) encoding single-chain IL-12 proteins comprised of p40 and p35 subunits were constructed. In a mouse model, a single gene gun vaccination with the combination of Hsp65 DNA and mIL-12 DNA provided a remarkably high degree of protection against challenge with virulent *Mycobacterium tuberculosis*; bacterial numbers were 100-fold lower in the lungs compared to BCG-vaccinated mice. To explore the clinical use of the DNA vaccines, we evaluated HVJ-liposome encapsulated Hsp65 DNA and mIL-12DNA (Hsp65 + mIL-12/HVJ). The HVJ-liposome method improved the protective efficacy of the Hsp65 DNA vaccine compared to gene gun vaccination. Hsp65 + mIL-12/HVJ induced CD8⁺ cytotoxic T lymphocyte activity against Hsp65 antigen. Most importantly, Hsp65 + mIL-12/HVJ vaccination resulted in a greater degree of protection than that evoked by BCG. This protective efficacy was associated with the emergence of IFN- γ -secreting T cells and activation of proliferative T cells and cytokines (IFN- γ and IL-2) production upon stimulation with Hsp65 and antigens from *M. tuberculosis*. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine.

© 2005 Elsevier Ltd. All rights reserved.

Keywords: Tuberculosis; DNA vaccine; HVJ-liposome

1. Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying each year from *Mycobac-*

terium tuberculosis infections. The only tuberculosis vaccine currently available is an attenuated strain of *Mycobacterium bovis* BCG. BCG continues to be widely administered to children in developing countries, yet its efficacy remains controversial, particularly against the pulmonary form of the disease in adults. In recent years, the increasing frequency of drug-resistant *M. tuberculosis* isolates has further complicated the clinical management of this disease. Clearly, a more effective vaccine for the control of tuberculosis is urgently needed.

* Corresponding author. Tel.: +81 72 252 3021; fax: +81 72 251 1372.

** Corresponding author. Tel.: +81 285 58 7339; fax: +81 285 44 6489.

E-mail addresses: shigeto@jichi.ac.jp (S. Yoshida), okm@kch.hosp.go.jp (M. Okada).

It is well established that protective immunity to *M. tuberculosis* depends on both CD4⁺ and CD8⁺ T cells [1–6]. Because DNA vaccination results in the generation of cellular immune responses, including those of a Th-1-type response, and protection in animal models of infectious diseases [7,8]. In fact, several human clinical trials have recently been initiated to test the efficacy of DNA vaccines against emerging and re-emerging infectious diseases including hepatitis B [9], malaria [10,11] and HIV infections [12]. DNA vaccination has also shown potential for the development of tuberculosis vaccines in the mouse model [13–16]. However, in a guinea pig model, which is arguably one of the most biologically relevant systems available for studying human pulmonary tuberculosis, DNA vaccines has not proven more efficacious than BCG [17]. The efficacy of any experimental tuberculosis vaccine remains to be evaluated in human clinical trials and, thus, a vaccine against tuberculosis is still anxiously awaited.

Mycobacterial heat shock protein 65 (Hsp65) is a potential target for protective immunity and has been extensively studied [18]. Several groups have reported that *hsp65* DNA vaccines can induce strong protective immune responses in mice against virulent *M. tuberculosis* infections [19–21]. Protection is attributed to the establishment of a cellular immune response dominated by Hsp65-specific T cells that both produce IFN- γ and are cytotoxic towards infected cells. Furthermore, Lowrie et al. have reported that this vaccine reduces bacterial loads in mice infected with *M. tuberculosis* when given therapeutically after infection [22]. Interleukin-12 (IL-12) is a cytokine with a major role in the induction of IFN- γ -dominated immune responses to microbial pathogens. Orme and colleagues have demonstrated the importance of IL-12 in generation of the protective response to tuberculosis [23]. Co-administration of the IL-12 gene, which participates in the induction of IFN- γ dominated immune responses to microbial pathogens, with various tuberculosis DNA vaccines including the *hsp65* DNA [20,24] and 35 K MW DNA [25] may boost the efficacy of these DNA vaccines to levels achieved with BCG in the mouse model, although inhibitory effect rather than synergistic effect on immunotherapy was observed in mice co-administrated with *hsp65* DNA vaccine plus the *IL-12* gene.

In order to explore the preclinical use of tuberculosis DNA vaccine combinations of the *IL-12* DNA with the *hsp65* DNA, we chose the viral-based hybrid antigen delivery system hemagglutinating virus of Japan (HVJ)-liposome because this delivery system results in a high transfection efficacy, repeated gene transfection without reduction of gene transfer efficiency *in vivo*, and no apparent toxicity. These characteristics of HVJ-liposomes support the feasibility of its clinical application not only for cancer gene therapy but also for DNA vaccinations. In a recent study, highly efficient transfection of muscle cells was observed for several weeks when pcDNA3 plasmid containing the human tumor antigen genes, *MAGE-1* and *MAGE-3*, were encapsulated in HVJ-liposomes and injected intramuscularly into mice [26]. Effective induction

of CD4⁺ T cell responses by a hepatitis B core particle-based HIV vaccine was achieved by subcutaneous administration of HVJ-liposomes in mice [27]. HVJ-liposomes were also very effective as a mucosal vaccine against HIV infection [28]. Thus, it is likely that HVJ proteins may be responsible for inducing a robust immune response. No side effects from repetitive injections of HVJ-liposomes into mice, rats or monkeys were observed.

We designed this study to clarify the clinical feasibility of HVJ-liposome-mediated DNA vaccines for tuberculosis. First, we clarify that co-administration of IL-12 DNA with Hsp65 DNA via gene gun delivery enhanced protection in mice compared with Hsp65 DNA alone. Second, we show that vaccination with HVJ-liposome encapsulated Hsp65 DNA resulted in better protection than did gene gun vaccination. Third, we demonstrate that HVJ-liposome encapsulated Hsp65 DNA and IL-12 DNA induce enhanced protective immunity in the mouse model compared to that seen with BCG. This protective efficacy was associated with the emergence of IFN- γ -secreting T cells upon stimulation with Hsp65 and purified protein derivative. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine. We also discuss in this paper the prospects of this HVJ-liposome-based DNA vaccine for testing in primate models [29] and, ultimately, in a clinical setting.

2. Materials and methods

2.1. Bacteria

M. tuberculosis strain H37Rv and *M. bovis* BCG Tokyo were kindly provided by Dr. I. Sugawara (JATA, Tokyo, Japan). *M. bovis* BCG Tokyo was maintained in synthetic Sauton medium (Wako Chemicals, Osaka, Japan). For the mouse infection studies, a single colony of *M. tuberculosis* H37Rv was grown in Middlebrook 7H9 (DIFCO Laboratories, Detroit, MI: lot 137971 XA MD) medium supplemented with albumin–dextrose complex and grown at 37 °C until approximately mid-log phase. Aliquots were stored at –80 °C and thawed at 10 days before use, grown to mid-log phase in 7H9 medium.

2.2. Reagents and antibodies

Purified protein derivative (PPD: lot T-3-4) was obtained from JAPAN BCG Co., Ltd. (Tokyo, Japan). Killed *M. tuberculosis* H37Ra (lot 13971XA) was obtained from DIFCO Laboratories. Fetal calf serum (FCS: lot AGC6341) was obtained from Hyclone (Logan, UT). Anti-L3T4, anti-Lyt2.2 monoclonal antibodies and anti-Thy1.2 antibody were kindly provided by Dr. K. Kuribayashi (Mie University, Tsu, Japan) and Dr. E. Nakayama (Okayama University, Okayama, Japan) [30].

2.3. Animals

Inbred and specific pathogen-free female BALB/c mice were purchased from Clea Japan Inc. (Tokyo, Japan). Mice were maintained in isolator cages, manipulated in laminar flow hoods and used between 8 and 10 weeks of age. Infected animals were housed in individual micro-isolator cages in a biosafety level (BL) 3 animal facility of the NHO Kinki-chuo Chest Medical Center.

2.4. Cell lines

COS-7 cells were kindly provided by Dr. H. Endoh (Jichi Medical School, Tochigi, Japan). COS-7 cells were maintained at 37°C in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, and antibiotics. A mouse mastocytoma cell line (P815: DBA/2 origin) was kindly provided by Dr. C.S. Henney (Fred Hutchinson Cancer Research Center, Seattle) [31]. A mouse macrophage cell line (J774.1: BALB/c origin) was kindly provided by Dr. P. Ralph (Sloan Kettering Cancer Inst., New York, NY) [32]. The P815 and J774.1 cells were maintained in RPMI 1640 medium (Flow Laboratories, Inc., Mclean, VA) supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 µg/ml) and 5×10^{-5} M 2-mercaptoethanol [33,34].

2.5. Plasmid construction

The *hsp65* gene was amplified from *M. tuberculosis* H37Rv genomic DNA by PCR using a set of primers, phsp65-F1 and phsp65-R1, and cloned into the *Bam*HI/*Not*I sites of pcDNA3.1 (+) (Invitrogen, San Diego, CA) to generate pcDNA-hsp65. pcDNA-hsp65 was designated as Hsp65 DNA in this text. For the construction of the *hsp65* gene fused with the mouse Igκ secretion signal sequence, the PCR product was cloned into the *Bam*HI/*Not*I sites of pcDNA-CS87 [35] to generate pcDNA-Ighsp65. pcDNA-Ighsp65 was designated as IgHsp65 DNA in this text. For the construction of the mouse IL-12 (mIL-12) *p40* and *p35* single-chain gene, the *mIL12p35* and *mIL12p40* genes were cloned from pcDNA-p40p35 [35] by PCR using sets of primers, pmIL12p35-F1 and pmIL12p35-R1, and pmIL12p40-F1 and pmIL12p40-R1, respectively, and cloned into pcDNA3.1 (+) to generate pcDNA-mIL12p40p35-F. pcDNA-mIL12p40p35-F was designated as mIL-12 DNA in this text. As a control, pcDNA-EGFP vector expressing the *EGFP* gene was used. Sequences of oligonucleotide primers used are available as request.

2.6. Protein production and antibody preparation

Recombinant Hsp65 (rHsp65) protein was expressed in *E. coli* BL21 (λDE3) and purified by affinity chromatography on Ni-NTA columns (Qiagen).

2.7. Transfection

DNA transfection of COS-7 cells was performed with the PolyFect Transfection Reagent (Qiagen) according to the manufacturer's instructions. After 24 h, supernatant and cells were harvested separately. Immunoprecipitation of cell lysates and supernatants with antibodies were performed as described previously [36]. Rat anti-mouse IL-12p70 (BD Biosciences Pharmingen, San Diego, CA) and mouse anti-rHsp65 polyclonal antibody were used for immunoprecipitation. For IL-12 bioassay, COS-7 cells (1×10^6 cells/plate) were plated into 60-mm cell culture plates and transfected with 2.5 µg of pcDNA 3.1, pcDNA-mIL12p40 + p35, or pcDNA-mIL12p40p35-F using the PolyFect Transfection Reagent. At 48 h after transfection, culture supernatants were collected and stored at -70°C until use. Various volumes of the supernatants were added to the mouse spleen cells (2×10^6 cells/ml). Murine culture supernatants after 60 h incubation were collected and the level of mouse IFN-γ measured using sandwich ELISA kits (BD Opt EIA™ Set. BD Biosciences Pharmingen), according to manufacturer's instructions.

2.8. Vaccination

2.8.1. Gene gun vaccination

Gold particles coated with plasmid DNAs and their cartridges were prepared as described previously [35]. The abdomen was shaved and gold particles coated with plasmid DNA (1 µg plasmid DNA per shot) was delivered once into the abdomen using a Helios Gene gun (Nippon Bio-Rad Laboratory, Tokyo, Japan) at a helium discharge pressure of 300 psi. A separate group was vaccinated once subcutaneously with 1×10^6 colony-forming units (CFU) of *M. bovis* BCG Tokyo strain.

2.8.2. HVJ-liposome vaccination

HVJ-liposomes were prepared as described previously [37]. The HVJ-liposome complex was aliquoted with 10% DMSO and stored at -70°C until use. HVJ-liposomes without plasmid DNA was used and designated as Empty/HVJ in this text. Groups of BALB/c mice were vaccinated three times at 3-week intervals with 100 µl of HVJ-liposome solution containing 50 µg of pcDNA-IgHsp65 and/or 50 µg of pcDNA-mIL12p40p35-F in the tibia both anterior muscles. A separate group was vaccinated once with 1×10^6 CFU *M. bovis* BCG Tokyo by subcutaneous injection at four different sites (left upper, right upper, left lower, right lower back) at the same time. HVJ-liposome DNA vaccines encapsulating pcDNA-IgHsp65, pcDNA-mIL12p40p35-F, or combination of pcDNA-IgHsp65 and pcDNA-mIL12p40p35-F was designated as IgHsp65/HVJ, mIL-12/HVJ, and IgHsp65 + mIL-12/HVJ, respectively, in this text.

2.9. Challenge infection of vaccinated animals and bacterial load determination

Mice were challenged by the intravenous route with 5×10^5 CFU of *M. tuberculosis* H37Rv 3 weeks after the third vaccination as described previously [38]. At 5 and 10 weeks after *M. tuberculosis* H37Rv challenge, the lungs, spleens, and livers were aseptically homogenized by using homogenizer in saline, and serial dilutions of the organ homogenates were plated on Ogawa agar (Kyokuto, Tokyo, Japan) or 7H11 Middlebrook agar (Kyokuto). Plates were sealed up and incubated at 37 °C and the number of CFU was counted 2 or 4 weeks later. Results are converted to log₁₀ values and log₁₀ [mean ± standard deviation (S.D.)] for CFU/organ/animal were calculated for each experimental group.

2.10. Histological analysis

The lungs were obtained from the mice, fixed with 10% buffered formalin, and embedded in paraffin. Each block was cut into 4 μm-thick sections and stained using hematoxylin and eosin. Semi-quantitative morphometric analysis of pathological slides was performed by our modified method of Dascher et al. [39] using a micrometer-attached microscope (Microphot-FXA, Nikon, Japan) [39,40]. The longer axis and minor axis of each granuloma in the field (×4 magnification) were measured. Longer axis to minor axis of each granuloma were multiplied and added up. Three random fields from each tissue section of mice and six random fields of guinea pigs were evaluated, and the average score of the fields was designated as the granuloma index ($\times 10^{-2}$ mm²). This method for the evaluation of granuloma area is significantly correlated with the granuloma area by other scanning method of hematoxylin and eosin section.

2.11. Tuberculosis-specific cytotoxic test using ⁵¹Cr release

Eight weeks after the final vaccination, CTL activity of spleen cells and mesenteric lymph node cells from vaccinated mice was assessed by using the ⁵¹Cr-release assay. P815 mastocytoma cells, which have the same major histocompatibility complex (MHC) (H-2^d) as BALB/c mice, were transfected with pcDNA-hsp65 and used as Hsp65 protein-expressing target cells. J774.1 macrophage cells were pulsed with *M. tuberculosis* (killed H37Ra) for 24 h and used as target cells. A total of 2×10^6 cells/ml effector splenic cells were treated with anti-CD8 antibody, anti-CD4 antibody or anti-Thy1.2 antibody followed by complement as described above. ⁵¹Cr release was assessed using the ⁵¹Cr-release assay [31,33] at the effector:target (E:T) ratio of 50:1. Spontaneous lysis (with medium alone) and maximum lysis (⁵¹Cr release after three cycles of freeze-thaw) were set up for background and targets.

Percent specific lysis was determined as:

$$\left[\frac{(\text{experimental release} - \text{spontaneous release})}{(\text{maximum release} - \text{spontaneous release})} \right] \times 100.$$

2.12. Proliferative responses of lymphocytes

Vaccinated mice were sacrificed immediately prior to challenge, and 1×10^5 single spleen cells were cultured in a 96-well flat bottom plate (Linbro) with rHsp65 protein (10 μg/ml) or PPD (20 μg/ml) for 60 h at 37 °C, and then pulsed with 1 μCi of [³H]thymidine per well for the final 12 h of incubation [30]. Cells were harvested onto glass wool fiber filters, and [³H]thymidine incorporation was measured using a Liquid Scintillation Counter LSC-6100 (ALOKA Co. Ltd., Tokyo, Japan).

2.13. Production of cytokines (IL-2 and IFN-γ)

Mouse cytokines were measured in quantitative ELISAs for IL-2 and IFN-γ as described previously [38]. Briefly, spleen cells from vaccinated mice were cultured at a concentration of 5×10^6 cells/ml in 200 μl of medium at various antigen concentrations. Culture supernatants were collected 48 h later and the levels of IFN-γ and IL-2 measured using sandwich ELISA kits (BD Opt EIA™), according to manufacturer's instructions.

2.14. ELISPOT assay

The spleens were removed aseptically from vaccinated mice three weeks after the third vaccination. Antigen-specific IFN-γ-producing cells were determined by ELISPOT as described previously [41]. Briefly, ELISPOT plates (MultiScreen IP Filtration plate MAIPS45; Millipore, Bedford, MA) were coated with anti-mouse IFN-γ MAb R4-6A2 (BD Biosciences Pharmingen). Spleen cells from vaccinated mice were suspended to 1×10^7 cells/ml (1×10^6 cells/well). In some experiments, the spleen cells from mice vaccinated with IgHsp65 + mL-12/HVJ were pre-incubated with anti-CD8 antibody or anti-CD4 antibody (1:50 dilution) for 15 min at 4 °C and then incubated with rabbit complement (1:10 dilution) (Cedarlane, Hornby, Ont., Canada) for 45 min at 37 °C as described previously [30,33]. The cells were placed in five wells into antibody-coated wells, and rHsp65 protein (10 μg/ml) or PPD (10 μg/ml) was added to each well. After 20 h of incubation at 37 °C, cells were removed by washing the plates, and the site of cytokine secretions was detected using biotinylated anti-mouse IFN-γ MAb XMG1.2 (BD Biosciences Pharmingen) and streptavidin-alkaline phosphatase conjugate (BD Biosciences Pharmingen). The enzyme reaction was developed with BCIP-NBT substrate (Vector Laboratories, Inc., Burlingame, CA). Spot-forming cells (SFCs) were enumerated using KS ELISPOT system (Carl Zeiss, Hallbergmoos, Germany).

2.15. Statistical analysis

Tukey–Kramer's HSD tests were used to compare \log_{10} value of CFU between groups following challenge and T cell responses between groups in ELISPOT assay. Student's *t* tests were performed to compare T cell responses between groups in T cell proliferation assay and granuloma formation between groups following challenge. A *P*-value of <0.05 was considered significant.

3. Results

3.1. In vitro expression of Hsp65 and IL-12

The DNA vaccines encoding mature and secreted forms of Hsp65 were constructed as Hsp65 DNA and IgHsp65 DNA, respectively. Hsp65 DNA contains the full-length *M. tuberculosis hsp65* gene. IgHsp65 DNA contains the full-length *M. tuberculosis hsp65* gene fused to the mouse Ig κ signal sequence. Each construct is driven by CMV promoter and terminated at a bovine growth hormone polyadenylation sequence. Hsp65 DNA or IgHsp65 DNA was transfected into COS-7 cells and cell lysates and supernatants were analyzed for the *hsp65* gene expression. As shown in Fig. 1A, the mature form was detected as a single band in cell lysates (lane 2), whereas the secreted form was detected as a doublet band in cell lysates (lane 3). The doublet of slightly higher molecular weight than the mature form is most likely due to incomplete cleavage of the Ig κ signal peptide in COS-7 cells because only a single band corresponding to the mature form was seen when HeLa cells or HepG2 cells were transfected with pcDNA-IgHsp65 (data not shown).

Based on the results of study reporting with high levels of IL-12 expression [42], we constructed a mouse IL-12 expression vector, mIL-12 DNA. The vector encodes mouse single-chain IL-12 protein comprised of p40 and p35 subunits linked by Gly₆Ser polypeptide linkers. As shown Fig. 1A, COS-7 cells transfected with mIL-12 DNA transiently expressed the mouse single-chain IL-12 protein with molecular weight of 80 kDa (lane 8). Quantitative analysis using ELISA showed that the COS-7 cells transfected with the mIL-12 DNA secreted four-fold higher levels of mIL-12p70 (125 ng/ml) than those transfected with from pcDNAmIL-12p40 + p35 (30 ng/ml), which previously constructed as a murine expression vector with IL-12 p40 and p35 expression cassettes in tandem array [35] (data not shown). Consistent with the mIL-12p70 expression level, the supernatant from the mIL-12 DNA transfectant cells induced 3.2-fold higher levels of IFN- γ from murine T lymphocytes than that from pcDNAmIL-12p40 + p35 transfectant cells (Fig. 1B). Thus, the mIL-12 DNA construct expresses biologically active IL-12, indicating that the single-chain IL-12 DNA is an effective DNA vaccine adjuvant capable of inducing primary Th-1 responses.

3.2. Evaluation of the best combination of Hsp65-based DNA vaccines with mIL-12 DNA for vaccine efficacy via gene gun

We compared the protective abilities of two versions of Hsp65-based DNA vaccine (Hsp65 DNA versus IgHsp65 DNA), and combinations with mIL-12 DNA (Hsp65 DNA versus Hsp65 DNA plus mIL-12 DNA, or IgHsp65 DNA versus IgHsp65 DNA plus mIL-12 DNA). Mice vaccinated with Hsp65 DNA, IgHsp65 DNA, and the combination with




Fig. 1. Expression and biological analysis of Hsp65 and mIL-12. (A) In vitro expression analysis of Hsp65 and mIL-12 from cells transiently transfected with DNA vaccines. COS-7 cells were transfected with EGFP DNA (lanes 1, 4 and 7), Hsp65 DNA (lanes 2 and 5), IgHsp65 DNA (lanes 3 and 6), and mILp40p35-F DNA (lane 8). Following metabolically labeling with [³⁵S]methionine, cell lysates (lanes 1, 2, 3, 7 and 8) and supernatants (lanes 4–6) were immunoprecipitated with mouse anti-Hsp65 polyclonal antibody (lanes 1–6) or rabbit anti-murine IL-12p70 antibody (lanes 7 and 8). (B) The biological activities of IL-12 expressed in transfected cell supernatants in vitro. Culture supernatants from COS-7 cells transfected with pcDNA3.1 (no insert empty vector), pcDNA-mIL12p40 + p35 or pcDNA-mIL12p40p35-F were added to the mouse spleen cells (2×10^6 cells/ml) at the final concentration of 4% (v/v) and incubated for 60 h. The levels of mouse IFN- γ were measured using sandwich ELISA kits as described in Section 2.




Fig. 2. The effect of a combination of mIL-12 expression vector and Hsp65-based DNA vaccines and comparison of different vaccines on the protective efficacy against challenge with *M. tuberculosis*. Groups of mice were vaccinated once with Hsp65 DNA, IgHsp65 DNA and a combination of mIL12 DNA via gene gun or three times with Hsp65/HVJ via intramuscular route and challenged intravenously with *M. tuberculosis* H37Rv as described in Section 2. Ten weeks after challenge, protection was measured by enumerating bacterial loads (CFU) in the lungs and spleen from vaccinated mice. Reduction of bacterial load was expressed as the mean log₁₀ difference in CFU in the organs of the naive and vaccinated mice. The statistical significance of differences between individual groups in the number of CFU was determined by Tukey–Kramer's HSD test ($n = 4-5$). * and **, the statistical significance of differences ($P < 0.05$ and $P < 0.01$) compared to Hsp65 DNA + mIL-12 DNA group, respectively; †, the statistical significance of differences ($P < 0.01$) of IgHsp65 DNA + mIL-12 DNA group compared to the naive, BCG, EGFP DNA, mIL12 DNA, Hsp65 DNA and IgHsp65 DNA groups; §, the statistical significance of differences of Hsp65/HVJ group compared to BCG group ($P < 0.05$) in the lungs; §§, the statistical significance of differences of Hsp65/HVJ group compared to Hsp65 DNA ($P < 0.01$) and BCG ($P < 0.05$) groups in the spleen.

mIL-12 DNA via gene gun were challenged intravenously with *M. tuberculosis* H37Rv. The bacterial loads of the naive and vaccinated mice were compared 10 weeks after challenge (Fig. 2). Consistent with the previous report by Lima et al. [43], gene gun vaccination with Hsp65 DNA alone did not result in significant protective immunity as assessed by the bacterial load in the lungs or spleen. Vaccination with IgHsp65 DNA, which encodes the additional mouse Ig κ signal sequence upstream of the *hsp65* gene, did not significantly improve the protective efficacy in the bacterial load in the lungs, although there was a modest decrease in the bacterial load in the spleen. In contrast, the combination with mIL-12 DNA markedly improved the protective efficacy both in the lungs and spleen ($P < 0.01$). In particular, vaccination of IgHsp65 DNA plus mIL-12 DNA conferred the greatest reduction of the bacterial load both in the lungs and spleen. Similar to IgHsp65 DNA plus mIL-12 DNA, the increased

protection in the lungs and spleen was also observed in mice vaccinated with Hsp65 DNA plus mIL-12 DNA compared to IgHsp65 DNA alone and mIL-12 DNA alone. Thus, a strong synergistic effect on protection was achieved when Hsp65 DNA was co-administrated with IL-12 DNA. It is notable that the prophylactic effect of IgHsp65 DNA plus mIL-12 DNA in the lungs was more than 100-fold greater than that of BCG. These vaccinations of IgHsp65 DNA plus mIL-12 DNA and Hsp65 DNA plus mIL-12 DNA also exerted the significant reduction in the liver compared to the naive ($P < 0.05$) and control EGFP DNA groups ($P < 0.01$), whereas there was no significant difference of the naive group compared with Hsp65 or mIL-12 group (data not shown). In mice vaccinated with IgHsp65 DNA plus mIL-12 DNA, increased protection in the lungs were also observed at 5 weeks after challenge, which was equivalent to that obtained by vaccination with BCG (data not shown).




Fig. 3. Mouse protection studies using HVJ-liposome vaccines. Groups of mice vaccinated with HVJ-liposome DNA or BCG were challenged by intravenous injection with *M. tuberculosis* H37Rv. Five weeks after challenge, protection was measured by enumerating the bacterial loads (CFU) in the lungs (A) and spleen (B) from vaccinated mice. Results are expressed as the mean $\log_{10} \pm$ S.D. of CFU. The statistical significance of differences between individual groups in the number of CFU was determined by Tukey–Kramer’s HSD test ($n=4-5$). * $P < 0.05$; ** $P < 0.01$; †, the statistical significance of differences ($P < 0.05$) of mL-12/HVJ group compared to BCG, Empty/HVJ, and Hsp65/HVJ groups in the lungs; ††, the statistical significance of differences ($P < 0.05$) of mL-12 DNA group compared to Empty/HVJ group in the spleens.

3.3. Comparison of the protective efficacy of gene gun versus HVJ-liposome delivery of Hsp65 DNA vaccines

We next compared methods of DNA vaccine delivery on vaccine efficacy at 10 weeks after challenge. Hsp65/HVJ vaccination and challenge experiments were conducted simultaneously with gene gun experiments. As shown in Fig. 2, Hsp65/HVJ vaccination significantly reduced the bacterial loads as compared to Hsp65 gene gun immunization in the spleen ($P < 0.01$). IgHsp65 gene gun immunization significantly reduced the bacterial loads as compared to Hsp65 gene gun immunization in the spleen ($P < 0.05$, data not shown). Therefore, we used IgHsp65/HVJ for further experiments.

3.4. Protective efficacy of HVJ-liposome DNA vaccines

At 5 and 10 weeks after intravenous challenge of *M. tuberculosis* H37Rv, the number of CFU in the lungs, spleen, and liver were determined. Fig. 3 shows the results of bacterial loads 5 weeks after challenge. Vaccination with mL-12/HVJ group resulted in significant protective immunity in the bacterial as compared to BCG, Empty/HVJ and Hsp65/HVJ groups

in the lung ($P < 0.05$) and as compared to Empty/HVJ group in the spleen ($P < 0.05$). Vaccination with IgHsp65 +mL-12/HVJ induced better protective immunity in the bacterial load both in the lungs and spleens than IgHsp65/HVJ alone and mL-12/HVJ alone. Thus, the synergistic effect of IgHsp65 DNA and mL-12 DNA resulted in improving the protective efficacy. At 10 weeks after challenge, the same reduction was also observed in these organs from mice vaccinated with IgHsp65 +mL-12/HVJ (data not shown). Body weights of vaccinated mice were similar in all vaccinated groups. Tissue weight of lungs, liver, and spleen in the IgHsp65 +mL-12/HVJ group were slightly lower than that from the naive mice (data not shown). In this experiment, BCG vaccination did not provide significant reduction of the bacterial load compared to the naive group. This may be due to the single-dose of vaccination used usually, the use of BCG Tokyo strain requires a three-dose vaccination to achieve 10 to 30-fold reduction of the bacterial loads compared to a non-vaccinated group. Although, 5 weeks after challenge, no reduction of bacterial loads was observed in IgHsp65/HVJ group compared with the naive control group, we confirmed the increased protection 10 weeks after challenge compared with the naive control group




Fig. 4. Histopathological analysis of vaccinated mice 10 weeks after *M. tuberculosis* challenge. Representative photomicrographs of lung tissue sections harvested from the naive control group (A) and from the IgHsp65 + mIL-12/HVJ group (B) are shown (10 weeks after *M. tuberculosis* challenge, hematoxylin and eosin staining, $\times 10$ objective). There were much infiltration of mononuclear cells and extensive parenchymal destruction by large, poorly demarcated granuloma in the lung from the naive control group. In the IgHsp65 + mIL-12/HVJ group, the lungs were less inflamed and only a few granuloma was observed. (C) Granuloma index of the naive control group and the IgHsp65+mIL-12/HVJ group in the lungs. Results are expressed as the mean \pm S.D. of triplicates of five mice per group. The statistical significance of differences between the groups was determined by Student's *t*-test. * $P < 0.05$ as compared with the naive control group.

at the same experiments (data not shown). These results indicate that co-vaccination with IL-12 DNA was effective for inducing protective immunity at as early as 5 weeks after challenge.

3.5. IgHsp65 + mIL-12/HVJ vaccination markedly reduced granuloma formation in the lung

In addition to the reduction of bacterial loads, the effects of vaccination on the mice were assessed by histological analysis. The granulomatous lesions in the lungs from IgHsp65 + mIL-12/HVJ mice were significantly less in number and size than from the naive control group (Fig. 4A and B). Quantitative evaluation of the granulomatous lesions clearly shows that IgHsp65 + mIL-12/HVJ vaccinated mice group exhibited significant reduction in granuloma index in the lungs, compared to the naive group ($P < 0.05$) (Fig. 4C). Thus IgHsp65 + mIL-12/HVJ vaccine provided significant

protection against the pulmonary pathology caused by *M. tuberculosis* infection.

3.6. HVJ-liposome DNA vaccines generated T-helper response and cytokine production

To investigate lymphocyte proliferative and cytokine responses induced by HVJ-liposome DNA vaccines, spleen cells from vaccinated mice were re-stimulated with antigen in vitro. As shown in Fig. 5, substantial lymphocyte proliferation was observed in response to rHsp65 protein in spleen cells from mice vaccinated with IgHsp65/HVJ or IgHsp65 + mIL-12/HVJ but not with the naive control. IgHsp65 + mIL-12/HVJ vaccination induced significantly better proliferative response to rHsp65 protein than did IgHsp65/HVJ vaccination ($P < 0.01$). In addition to lymphocyte proliferative responses, vaccination with IgHsp65 + mIL-12/HVJ induced elevated levels of IFN- γ and




Fig. 5. The effect of vaccination with HVJ-liposome DNA on T cell proliferation. Proliferative responses of splenic lymphocytes from mice vaccinated with IgHsp65/HVJ, mL-12/HVJ, IgHsp65 + mL-12/HVJ, BCG, or Empty/HVJ. Incorporation of [³H]thymidine in response to rHsp65 protein (black bars) or PPD (gray bar) was measured as described in Section 2. Results are expressed as the mean \pm S.D. of triplicates of three mice per group. The statistical significance of differences between individual groups in T cell proliferation was determined by Tukey–Kramer's HSD test. The statistical significance of differences ($P < 0.01$) compared to the naive and BCG groups are indicated as (*) and (†), respectively.

IL-2 in response to rHsp65 protein, but not with the naive control or BCG group (Fig. 6). In response to PPD, vaccination with IgHsp65 + mL-12/HVJ markedly increased both IFN- γ and IL-2 production as compared to the BCG group. Moderate but significant levels of IFN- γ and IL-2 were also induced in Hsp65/HVJ vaccination in response to Hsp65 protein and PPD. Thus, the synergistic effect of IgHsp65 DNA and mL-12 DNA resulted in the strongest response not only to T cell proliferation but also to cytokine production.

3.7. HVJ-liposome DNA vaccines generated cytotoxic CD8⁺ T cells

Because CD8⁺ CTLs have been considered critical effectors of protective immunity to *M. tuberculosis*, it was of interest to determine whether a tuberculosis specific response could be induced in the vaccinated mice. We characterized CD8⁺ T cells specific for Hsp65, PPD or killed *M. tuberculosis* by using a conventional ⁵¹Cr release assay in the




Fig. 6. IFN- γ (A) and IL-2 (B) production in spleen cell culture supernatants from vaccinated mice following stimulation with rHsp65 protein and PPD. Spleen cell cultures were stimulated with rHsp65 protein (black bars) or PPD (white bars) for 48 h, and the levels of IFN- γ and IL-2 production were determined by ELISA. Results are expressed as the mean \pm S.D. of duplicates of three mice per group with antigens minus the mean \pm S.D. of triplicates of three mice per group with medium alone.




Fig. 7. Induction of CD8⁺ CTL specific for Hsp65 protein and *M. tuberculosis* by vaccination with IgHsp65 + mIL-12/HVJ. Spleen cells from the naive, BCG-, and IgHsp65 + mIL-12/HVJ-vaccinated mice were obtained 8 weeks after the final vaccination. Cytotoxicity was assayed as release of radioactivity from ⁵¹Cr-labeled J774.1 macrophages that had phagocytosed *M. tuberculosis* (killed H37Ra) (A) or from ⁵¹Cr-labeled P815 target that had been transfected with Hsp65 DNA (B) using a conventional ⁵¹Cr release assay at E:T ratio of 50:1. The effector cells were pre-incubated with anti-CD8, anti-CD4 or anti-Thy1.2 antibody, followed by treatment with complement. Percent specific lysis was determined as: [(experimental release–medium control release)/(maximum release–medium control release)] × 100. Ab: antibody; C: complement; (-), non-treatment.

absence of re-stimulation. As shown in Fig. 7, high levels of Hsp65- and *M. tuberculosis*-CTL specific lysis against J774.1 macrophages phagocytosed *M. tuberculosis* and P815 mastocytomas transfected with Hsp65 DNA were detected in mice vaccinated with IgHsp65 + mIL-12/HVJ, whereas little CTL response was detectable in either the naive or

BCG-vaccinated mice. In vitro depletion of CD8⁺ T cells eliminated the specific lysis. Depletion of CD4⁺ T cells had no effect. Stronger (more than twenty percent) cytotoxicity against Hsp65 was detected in the spleen cells from mice 2 weeks after the last vaccination with IgHsp65 + mIL-12/HVJ (data not shown). These results indicate that IgHsp65 + mIL-




Fig. 8. ELISPOT assay for IFN-γ antigen-specific responses in the spleens of vaccinated mice following stimulation with rHsp65 protein and PPD. Spleen cell cultures were stimulated with rHsp65 protein or PPD for 20 h or pre-incubated with anti-CD8 antibody or anti-CD4 antibody followed by treatment with complement and then stimulated with rHsp65 protein for 20 h. The number of IFN-γ-secreting cells specific for rHsp65 protein (black bars) or PPD (white bars) per million cells were determined individually by ELISPOT assay. Results are expressed as the mean ± S.D. of five-wells of three mice per group. The statistical significance of differences between individual groups in the number of IFN-γ-secreting cells was determined by Tukey–Kramer’s HSD test. The statistical significance of differences ($P < 0.01$) compared to the naive and BCG groups are indicated as (*) and (†), respectively.

12/HVJ vaccine induced long-term immune response with strong CD8⁺ CTL activity.

3.8. ELISPOT assay

In order to determine whether enhanced protection was associated with increased IFN- γ production, the frequency of IFN- γ -secreting cells was enumerated by ELISPOT. Vaccination with IgHsp65/HVJ and IgHsp65 + mL-12/HVJ resulted in a marked increase of IFN- γ secreting cells following stimulation with rHsp65 protein (Fig. 8). Moreover, the increase of IFN- γ secreting cells was also seen in IgHsp65/HVJ and IgHsp65 + mL-12/HVJ groups following stimulation with PPD. These results indicate that vaccination with IgHsp65/HVJ and IgHsp65 + mL-12/HVJ activated antigen-specific T cells producing IFN- γ . Depletion of CD8⁺ cells from responder cells by treatment with anti-CD8 antibody and complement almost abrogated the IFN- γ producing cells. In contrast, an increase in the number of IFN- γ producing cells was observed in the responder cells when treated with anti-CD4 antibody and complement. BCG vaccination resulted in significant increase of IFN- γ secreting cells following stimulation with PPD but not rHsp65 protein. These data indicate that the protective efficacy of IgHsp65 + mL-12/HVJ is strongly associated with the emergence of IFN- γ -secreting cells upon stimulation with Hsp65. Taken together, vaccination with IgHsp65 + mL-12/HVJ capable of augmenting T cell activation and frequency of IFN- γ -secreting cells proves to reduce bacterial burden and pathology in the lungs—all to an extent greater than those achieved by vaccination with BCG.

4. Discussion

In the first stage of this study, we evaluated the protective efficacy of Hsp65 DNA vaccines via gene gun vaccination. One of the significant findings of the present study is that a single gene gun vaccination with the combination of IgHsp65 DNA and mL-12 DNA led to a remarkably high degree of protection against intravenous challenge infection with virulent *M. tuberculosis*; bacterial numbers declined exponentially in internal organs and were 100-fold lower in the lungs than in BCG-vaccinated mice. Consistent with previous studies [43], gene gun vaccination with Hsp65 DNA alone did not promote reduction in bacterial burden compared to the naive mice. However, co-vaccination of Hsp65 DNA or IgHsp65 DNA plus mL-12 DNA significantly improved the protective efficacy compared to either Hsp65 DNA alone or IgHsp65 DNA alone. Since the importance of IL-12 in the control of mycobacterial infections has been well documented, these results are consistent with other studies describing an adjuvant effect of IL-12 gene when administered in combination with various tuberculosis DNA vaccines [20,24,25]. The mL-12 DNA, which express both p40 and p35 chains as a single molecule, is able to induce four-fold higher levels

of IFN- γ from mouse T lymphocytes than mL12p40 + p35, which has previously been constructed as a murine expression vector with IL-12 p40 and p35 expression cassettes in tandem array [35]. Culture supernatants from the mL-12 DNA-transfected COS-7 cells were effectively induced IFN- γ from mouse spleen cells. Thus, the improved expression levels of IL-12 DNA and the biologically active IL-12 explain the enhanced protection observed.

The second stage of this study demonstrated the protective efficacy of HVJ-liposome DNA vaccines in mouse and guinea pig models. We originally developed HVJ-liposomes, a viral/nonviral hybrid vector, as a gene transfer vector for cancer gene therapy. HVJ-liposome gene transfer method can deliver DNA directly and efficiently into host cells in vivo by means of the HVJ virus cell fusion machinery. We found that HVJ-liposome-mediated gene transfer was 30–100 times more efficient in gene expression in skeletal muscle than naked DNA transfer (unpublished data) and over three times more efficient in delivering intact oligodeoxyribonucleotide within the nuclei of transfected cells than Lipofectin[®], a different cation liposome [44]. In addition to its high transfection efficiency, there are numerous safety advantages of HVJ-liposomes including: (i) no apparent toxicity or inflammation and (ii) repeated gene transfection without reduction of transfection efficiency. In fact, no significant adverse effects were induced in monkeys by intravenous injection of HVJ-liposomes [45]. Using this novel vector, we observed the enhancement of protection conferred by Hsp65 DNA compared to gene gun vaccination. This result is encouraging for the development of a novel tuberculosis DNA vaccine that is applicable both for prophylactic and therapeutic uses with no side-effects after repeated injections.

The most significant finding of this study is that vaccination with IgHsp65 + IL-12/HVJ provided greater protective efficacy than vaccination with BCG. In the mouse model, IgHsp65 + mL-12/HVJ preferentially triggered a Th1 type T helper response, characterized by elevated levels of IFN- γ and IL-2, and augmentation of lymphocyte proliferation. After challenge, vaccination with IgHsp65 + mL-12/HVJ resulted in a greater degree of protection than that evoked by BCG. This protective efficacy was associated with the emergence of IFN- γ -secreting T cells directed against Hsp65 and PPD. CD8⁺ CTL activity against macrophage target cells, which had previously phagocytosed *M. tuberculosis* or expressed Hsp65 protein, was still observed in the spleen cells from mice vaccinated with IgHsp65 + mL-12/HVJ at 8 weeks after the final vaccination, IgHsp65 + mL-12/HVJ vaccine capable of augmenting long-term immune response with anti-tuberculosis CTL activity proves IgHsp65 + mL12/HVJ to be a promising tuberculosis vaccine candidate.

Although the *hsp65* DNA vaccines have been shown to have significant promise as a new prophylactic vaccine against tuberculosis [19,21,46], negative outcomes have also been reported [47,48]. In the case of vaccination with *hsp65* DNA alone, our results are consistent with the previous report

that vaccination with *hsp65* DNA alone did not provide significant protective effect in the bacterial load in the lung either in the mouse model or in the guinea pig model [43,47]. However, as described above, the combination with mL-12 DNA expressing biologically active IL-12 and the use of HVJ-liposome as a DNA vaccine delivery system remarkably improved the protective efficacy. In addition, our preliminary results of a guinea pig model in the collaborative study with Dr. D. McMurray (Texas A&M University) show that vaccination with IgHsp65 + guinea pig IL-12 (gpIL-12)/HVJ provided better protection against the pulmonary pathology caused by aerosol challenge with *M. tuberculosis* than did BCG vaccination (data not shown). For immunotherapeutic use, *hsp60/lep* DNA vaccine (*hsp65* DNA derived from *Mycobacterium leprae*) has been shown to be effective in a Cornel-type model [22], although others have argued that this vaccine induced progressively severe pulmonary necrosis in the model [48]. In support of the effectiveness, when administered to mice or SCID-PBL/hu mice [49] already infected with *M. tuberculosis*, neither IgHsp65 + mL-12/HVJ vaccine nor IgHsp65 + human IL-12 (hIL-12)/HVJ vaccine, respectively, resulted in exacerbation of the granulomatous response in the lungs (unpublished data). Moreover, therapeutic administration of IgHsp65 + mL-12/HVJ resulted in significant reduction of bacterial loads (paper in submission). The pathological parameter of protection included reductions in the mean lung granulomatous lesion score in our study. In parallel with the protective efficacy of HVJ-liposome vaccines on bacterial loads, histopathological analysis shows that mice vaccinated with IgHsp65 + mL-12/HVJ had fewer and smaller lesions in the lung and significantly less lung granuloma than the naive mice. These results suggest that severe toxicities (Koch phenomenon) could not be induced by this vaccine. One possible explanation for these diverging results may be different *hsp65* DNA construct (secreted form versus cytoplasmic form; derived from *M. tuberculosis* versus *M. leprae*), different mL-12 DNA construct (p40p35 fusion form versus p40-p35 tandem form), and different vaccine delivery (HVJ-liposome versus gene gun or naked DNA).

In conclusion, we demonstrate the development of a novel HVJ-liposome DNA vaccine encapsulating Hsp65 DNA plus IL-12 DNA. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to the currently available BCG vaccine. The goal of our study is to develop a new tuberculosis vaccine superior to BCG. To this aim, we believe that the protective efficacy and protective immune responses for vaccine candidates should be addressed in larger animals, such as non-human primates, before proceeding to human clinical trials. Although other DNA vaccine candidates that appear to protect against virulent *M. tuberculosis* in mice better than BCG have failed to provide better protection than BCG in guinea pigs against aerosol challenge of a low dose of virulent *M. tuberculosis* [47,50,51], some of them are being prepared to enter early human clinical trials [52]. More recently, we evaluated the IgHsp65 + hIL-12/HVJ vaccine in the cynomolgus

monkey model [29], which is currently the best non-human primate animal model of human tuberculosis. Monkeys were subsequently challenged with virulent *M. tuberculosis* by the intra-tracheal route after the third vaccination. This challenge dose normally causes death from acute respiratory infection within 4–6 months. In this particular experiment, monkeys vaccinated with IgHsp65 + hIL-12/HVJ induced Hsp65-specific T cell proliferation and improvement of chest X-P findings, resulting in an increased survival for over a year, superior to BCG group [29]. Thus, we are taking advantage of the availability of multiple animal models (mouse, guinea pig, and monkey) to accumulate essential data of the HVJ-liposome DNA vaccine, including the vaccine efficacy and safety, for up-coming Phase I clinical trials.

Acknowledgements

We thank Dr. D. McMurray (Texas A&M University) for valuable scientific input and critical reading of the manuscript. We thank H. Takai, C. Okada, Y. Fukunaga, Y. Sakaguchi, J. Mori, I. Furukawa, K. Yamada, Y. Inanaga, M. Izumiya, K. Ishizaki, K. Matsumoto, K. Hara for assistance with tuberculosis infection study in vivo as well as in vitro and taking care of experimental animals. We also thank M. Tomita, E. Kurokawa, T. Teramoto, Dr. S. Yamamoto for a helpful support with histopathological study and culture of *M. tuberculosis*. We thank C. Seki for assistance with plasmid DNA preparation. This study was supported by a grant Health and Labour Science Research Grants for Research on Emerging and Re-emerging Infectious Diseases from Ministry of Health, Labour and Welfare to M.O. (H11-shinko-2, H14-shinko-1) from the Ministry of Health, Labour and Welfare, Japan; Grant for Scientific Research(C), Grant-in-Aid for Scientific Research, from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Grant for Japan-USA Tuberculosis Leprosy collaborative Study from the Ministry of Foreign Affairs; Grant for the Osaka Tuberculosis Foundation; Grant for collaborative base study of National Hospital from the Ministry of Welfare and Health; Grant for Clinical Research from the Ministry of Health and Welfare. It was also supported by an international collaborative study grant from Human Science foundation and by a grant from Sankyo Life Science foundation to S.Y.

References

- [1] Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001;19:93–129.
- [2] Hess J, Schaible U, Raupach B, Kaufmann SH. Exploiting the immune system: toward new vaccines against intracellular bacteria. *Adv Immunol* 2000;75:1–88.
- [3] Geluk A, van Meijgaarden KE, Franken KL, Drijfhout JW, D'Souza S, Necker A, et al. Identification of major epitopes of *Mycobacterium tuberculosis* AG85B that are recognized by HLA-A*0201-restricted CD8⁺ T cells in HLA-transgenic mice and humans. *J Immunol* 2000;165(11):6463–71.

- [4] Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for *Mycobacterium tuberculosis*. Proc Natl Acad Sci USA 1998;95(1):270–5.
- [5] Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003;21:29–70.
- [6] McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against *Mycobacterium tuberculosis* induced by dendritic cells pulsed with both CD8(+) and CD4(+) T-cell epitopes from antigen 85A. Infect Immun 2002;70(3):1623–6.
- [7] Srivastava IK, Liu MA. Gene vaccines. Ann Intern Med 2003;138(7):550–9.
- [8] Okada M, Kishimoto T, editors. The potential application and limitation of cytokine/growth factor manipulation in cancer therapy. In: Puzstai L, Lewis C, Yap E, editors. Cell proliferation in Cancer: Regulatory Mechanisms of Neoplastic Cell Growth. Oxford University Press, 1996. p. 218–244.
- [9] Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19(7–8):764–78.
- [10] Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000;18(18):1893–901.
- [11] Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 2004;199:126–43.
- [12] Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin Immunol 1999;90(1):100–7.
- [13] Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998;2(12):971–8.
- [14] Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999;1(1):30–3.
- [15] Orme IM. The search for new vaccines against tuberculosis. J Leukoc Biol 2001;70(1):1–10.
- [16] Doherty TM, Andersen P. Tuberculosis vaccine development. Curr Opin Pulm Med 2002;8(3):183–7.
- [17] McMurray DM. Guinea pig model of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington, DC: ASM Press; 1994. p. 113–34.
- [18] Silva CL. The potential use of heat-shock proteins to vaccinate against mycobacterial infections. Microbes Infect 1999;1(6):429–35.
- [19] Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996;2(8):888–92.
- [20] Baek KM, Ko SY, Lee M, Lee JS, Kim JO, Ko HJ, et al. Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against *Mycobacterium tuberculosis* heat shock protein 65. Vaccine 2003;21(25–26):3684–9.
- [21] Lima KM, Santos SA, Lima VM, Coelho-Castelo AA, Rodrigues Jr JM, Silva CL. Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of *Mycobacterium tuberculosis*. Gene Ther 2003;10(8):678–85.
- [22] Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999;400(6741):269–71.
- [23] Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med 1997;186(1):39–45.
- [24] Palendira U, Kamath AT, Feng CG, Martin E, Chaplin PJ, Triccas JA, et al. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and *Mycobacterium bovis* BCG vaccines against *Mycobacterium tuberculosis*. Infect Immun 2002;70(4):1949–56.
- [25] Martin E, Kamath AT, Briscoe H, Britton WJ. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than *Mycobacterium bovis* (bacille Calmette-Guerin) in protecting against systemic *Mycobacterium avium* infection. Immunology 2003;109(2):308–14.
- [26] Tanaka M, Kaneda Y, Fujii S, Yamano T, Hashimoto K, Huang SK, et al. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 2002;5(3):291–9.
- [27] Takeda S, Shiosaki K, Kaneda Y, Nakasatomi T, Yoshizaki H, Someya K, et al. Hemagglutinating virus of Japan protein is efficient for induction of CD4(+) T-cell response by a hepatitis B core particle-based HIV vaccine. Clin Immunol 2004;112(1):92–105.
- [28] Sakaue G, Hiroi T, Nakagawa Y, Someya K, Iwatani K, Sawa Y, et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003;170(1):495–502.
- [29] Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005;23(17–18):2132–5.
- [30] Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141(5):1543–9.
- [31] Okada M, Klimpel GR, Kuppers RC, Henney CS. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol 1979;122(6):2527–33.
- [32] Okada M, Kishimoto T, Igarashi T, Teranishi T, Yamamura Y. LPS- or 8Br-cyclic AMP-induced production of T cell-activating factor(s) in macrophage tumor cell line J774.1. J Immunol 1978;120(4):1097–101.
- [33] Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci USA 1981;78(12):7717–21.
- [34] Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983;157(2):583–90.
- [35] Yoshida S, Kashiwamura S, Hosoya Y, Luo E, Matsuoka H, Ishii A, et al. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of *Plasmodium berghei* sporozoite. Biochem Biophys Res Commun 2000;271(1):107–15.
- [36] Yoshida S, Lee LF, Yanagida N, Nazerian K. The glycoprotein B genes of Marek's disease virus serotypes 2 and 3: identification and expression by recombinant fowlpox viruses. Virology 1994;200(2):484–93.
- [37] Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997;8(17):2133–41.
- [38] Miki K, Nagata T, Tanaka T, Kim YH, Uchijima M, Ohara N, et al. Induction of protective cellular immunity against *Mycobacterium tuberculosis* by recombinant attenuated self-destructing *Listeria monocytogenes* strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect Immun 2004;72(4):2014–21.
- [39] Dascher CC, Hiromatsu K, Xiong X, Morehouse C, Watts G, Liu G, et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol 2003;15(8):915–25.

- [40] Sugawara I, Udagawa T, Hua SC, Reza-Gholizadeh M, Otomo K, Saito Y, et al. Pulmonary granulomas of guinea pigs induced by inhalation exposure of heat-treated BCG Pasteur, purified trehalose dimycolate and methyl ketomycolate. *J Med Microbiol* 2002;51(2):131–7.
- [41] Yoshida S, Kondoh D, Arai E, Matsuoka H, Seki C, Tanaka T, et al. Baculovirus virions displaying *Plasmodium berghei* circumsporozoite protein protect mice against malaria sporozoite infection. *Virology* 2003;316(1):161–70.
- [42] Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. *Nat Biotechnol* 1997;15(1):35–40.
- [43] Lima KM, dos Santos SA, Santos RR, Brandao IT, Rodrigues JM, Silva CL. Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo. *Vaccine* 2003;22(1):49–56.
- [44] Nakamura N, Hart DA, Frank CB, Marchuk LL, Shrive NG, Ota N, et al. Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition. *J Biochem (Tokyo)* 2001;129(5):755–9.
- [45] Tsuboniwa N, Morishita R, Hirano T, Fujimoto J, Furukawa S, Kikumori M, et al. Safety evaluation of hemagglutinating virus of Japan-artificial viral envelope liposomes in nonhuman primates. *Hum Gene Ther* 2001;12(5):469–87.
- [46] Vordermeier HM, Lowrie DB, Hewinson RG. Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting. *Vet Microbiol* 2003;93(4):349–59.
- [47] Turner OC, Roberts AD, Frank AA, Phalen SW, McMurray DM, Content J, et al. Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of *Mycobacterium tuberculosis*. *Infect Immun* 2000;68(6):3674–9.
- [48] Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. *Infect Immun* 2003;71(4):2192–8.
- [49] Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. *Cancer Res* 1997;57(7):1335–43.
- [50] Baldwin SL, D'Souza C, Roberts AD, Kelly BP, Frank AA, Lui MA, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. *Infect Immun* 1998;66(6):2951–9.
- [51] Chambers MA, Williams A, Hatch G, Gavier-Widen D, Hall G, Huygen K, et al. Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with *Mycobacterium bovis*. *Infect Immun* 2002;70(4):2159–65.
- [52] National Institute of Allergy and Infectious Diseases. The Jordan Report: 20th Anniversary Accelerated Development of vaccines: <http://www.niaid.nih.gov/dmid/vaccines/jordan20/jordan20_2002.pdf>.



Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB

Masaji Okada^{a,*}, Yoko Kita^a, Toshihiro Nakajima^b, Noriko Kanamaru^a, Satomi Hashimoto^a, Tetsuji Nagasawa^b, Yasufumi Kaneda^c, Shigeto Yoshida^d, Yasuko Nishida^a, Reiko Fukamizu^a, Yoshie Tsunai^a, Ruriko Inoue^a, Hitoshi Nakatani^a, Yumi Namie^a, Junko Yamada^a, Kyoko Takao^a, Ritsuko Asai^a, Ryoko Asaki^a, Makoto Matsumoto^e, David N. McMurray^f, E.C. Dela Cruz^g, E.V. Tan^g, R.M. Abalos^g, J.A. Burgos^g, Robert Gelber^g, Mitsunori Sakatani^a

^a Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591-8555, Japan

^b Ikeda Laboratory GenomIdea Inc., 1-8-31, Midorigaoka, Ikeda, Osaka 530-0043, Japan

^c Division of Gene Therapy Science Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

^d Department of Medical Zoology, Jichi-Med.Sch, 3311-1 Yakushiji, Minamikawachi-machi, Tochigi 329-0498, Japan

^e Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-019, Japan

^f Texas A & M University, System Health Science Center, College of Medicine, College Station, TX 77843-1114, USA

^g Leonard Wood Memorial, Jagobiao, Mandaue City, Cebu 6000, Philippines

Abstract

We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ). This vaccine provided remarkable protective efficacy in mouse and guinea pig models compared to the BCG vaccine, on the basis of an induction of the CTL activity and improvement of the histopathological tuberculosis lesions, respectively. Furthermore, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis. This novel vaccine provided a higher level of the protective efficacy than BCG based upon the assessment of mortality, the ESR, body weight, chest X-ray findings and immune responses. Furthermore, the combination of HSP65 + IL-12/HVJ and BCG by the priming-booster method showed a synergistic effect in the TB-infected cynomolgus monkey (100% survival). These data indicate that our novel DNA vaccine might be useful against *Mycobacterium tuberculosis* for human clinical trials.

© 2007 Published by Elsevier Ltd.

Keywords: HSP65 DNA + IL-12 DNA vaccine; Tuberculosis; Monkey

1. Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying every year from *Mycobacterium tuberculosis* (TB) infections. The only tuberculosis vaccine currently available is an attenuated strain of *Mycobacterium bovis* BCG (BCG), although its efficacy against adult TB

disease remains controversial. Therefore, we have recently developed a novel TB vaccine, a DNA vaccine expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-liposome (HSP65 + IL-12/HVJ). The vaccine was 100 fold more efficient than BCG in the mouse model on the basis of the elimination of *M. tuberculosis* mediated by the induction of CTL [1]. A nonhuman primate model of TB will provide critical information for vaccine development. In fact, in the previous study we evaluated the protective

* Corresponding author. Tel.: +81 72 252 302; fax: +81 72 21 2153.
E-mail address: okm@kch.hosp.go.jp (M. Okada).

efficacy of HSP65 + IL-12/HVJ in the cynomolgus monkey model, which is an excellent model of human tuberculosis [2,3]. In the present study, we evaluated the synergistic effect of the HSP65 + IL-12/HVJ and BCG using a priming-booster method in the TB-infected cynomolgus monkey. The combination of the two vaccines showed a very strong prophylactic effect in monkeys challenged with *M. tuberculosis* (100% survival), as we have seen previously in the mouse model of TB.

2. Materials and methods

DNA vaccines encoding *M. tuberculosis* HSP65 and human IL-12 were encapsulated into HVJ-liposomes [4]. CTL activity was assessed by ⁵¹Cr-release [3,5]. A total of 44 cynomolgus monkeys were housed in a BL 3 animal facility of the Leonard Wood Memorial Research Center. 12 monkeys population in first experiment and 32 monkeys population in second experiment are different. The animals were vaccinated three times with either the HVJ-liposome with expression plasmids of HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 µg i.m.), BCG Tokyo (1 × 10⁶ CFU i.d), or saline (Fig. 1A). One month after the third vaccination, the mon-




Fig. 1. (A) Evaluation of vaccine efficacy using cynomolgus monkey. Groups of animals were vaccinated three times with either the HVJ-liposome combination with HSP65 DNA plus human IL-12 DNA (HSP65 + hIL-12/HVJ: 400 µg i.m.), BCG Tokyo (1 × 10⁶ CFU i.d), or saline (A). One month after the third vaccination, monkeys were challenged with the *M. tuberculosis* Erdman strain (5 × 10²) by intratracheally instillation, erythrocyte sedimentation rate (ESR), body weight, chest X-ray, immune responses, DTH reaction against PPD, and survival periods were examined during 12–16 months. (B) Survival of cynomolgus cynomolgus monkeys immunized with HVJ-liposome/HSP65 + IL-12DNA vaccine. Cynomolgus monkey (4 monkeys/group) were immunized three times (every 3 weeks) with (1) HVJ-liposome/HSP65 DNA + IL-12 DNA vaccine (●-●), (2) saline (□-□) as control group as described in Section 2. One month after last immunization, *M. tuberculosis* (Erdman strain 5 × 10²) was challenged by intratracheally instillation. Survival was studied more than 14 months.

keys were challenged with the *M. tuberculosis* Erdman strain (5 × 10²) by intratracheal instillation. Erythrocyte sedimentation rate (ESR), body weight, chest X-rays, immune responses, DTH reaction against PPD, and survival periods were examined for 12–16 months [2,3].

3. Results

The purpose of this study was to evaluate a TB vaccine we have developed in a nonhuman primate TB model infected with *M. tuberculosis*. To this end, a total of 12 monkeys were in the first experiment vaccinated either with HSP65 + hIL-12/HVJ, BCG, or saline, followed by the TB challenge by intratracheal instillation. Fig. 1B shows the survival rate of the vaccinated monkeys after infection. All monkeys in the control group (saline, n=4) died within 8 months, while 2 monkeys in the HSP65 + hIL-12/HVJ group (n=4) as well as BCG group (n=4) survived more than 14 months post-infection (the termination period of the experiment). Furthermore, in the second experiment using 32 monkeys the protective efficacy of the HSP65 + IL-12/HVJ and BCG using the priming-booster method in the TB infected cynomolgus monkeys was very strong. All four monkeys from the group of BCG-priming and the DNA vaccine (HVJ-liposome/HSP65 + IL-12 DNA vaccine) booster were alive more than 12 months post-infection (Fig. 2). In contrast, only 2 monkeys out of 6 from the BCG Tokyo group





Fig. 2. Protective efficacy of HSP65 + IL-12/HVJ and BCG using priming-booster method against TB challenged cynomolgus monkeys. Group of animals were vaccinated three times (every 3 weeks) with (1) BCG Tokyo, (2) Hsp65 + IL-12/HVJ, (3) Hsp65 + IL-12/HVJ = G1 (—) BCG prime-HVJ/DNA booster group; (1) Hsp65 + IL-12/HVJ, (2) Hsp65 + IL-12/HVJ, (3) BCG = G2 (—) HVJ/DNA prime-BCG booster group; (1) Hsp65 + IL-12/HVJ, (2) Hsp65 + IL-12/HVJ, (3) Hsp65 + IL-12/HVJ = G3 (—); (1) BCG, (2) saline, (3) saline = G4 (---) G4 group animals were vaccinated with BCG once; (1) saline, (2) saline, (3) saline = G5. (—) One month after the third vaccination, monkey were challenged with the *M. tuberculosis*. Kaplan-Meier's method (Logrank test) was used to compare the survival of each groups. (G1–G4, p 0.05; G1–G2, p 0.13; G1–G3, p 0.32; G1–G5, p 0.12; G2–G4, p 0.82; G3–G4, p 0.30; G3–G5, p 0.44; G4–G5, p 0.88).



The Development of Novel Vaccines for M.tuberculosis using animal models




Fig. 3. (A) Improvement of erythrocyte sedimentation rate (ESR) in the cynomolgus monkeys immunized with HVJ-liposome/HSP65 DNA + IL-12 DNA vaccine. Cynomolgus monkeys were immunized and challenged as described in Fig. 2. Elevation of ESR of all monkeys was evaluated every month and maximum values of BSR in each monkeys were shown. (B) The development of novel vaccines for *M. tuberculosis* using animal models.

63 were alive (33% survival). 50% of the monkeys from the
 64 saline control group and DNA vaccine-priming and the BCG
 65 Tokyo vaccine booster group, respectively, were alive more
 66 than 12 months in the study. In addition, both HSP65 + hIL-
 67 12/HVJ improved ESR and chest X-ray findings (Fig. 3A).
 68 IL-2 and IFN- γ production were augmented in the group
 69 vaccinated with HSP65 + hIL-12/HVJ (data not shown). Fur-
 70 thermore, proliferation of PBL was strongly enhanced. Taken
 71 together, these results clearly demonstrate that BCG priming
 72 and the HSP65 + hIL-12/HVJ booster could provide

extremely strong protective efficacy against *M. tuberculosis*
 in the cynomolgus monkey model.

4. Discussion

The HSP65 + hIL-12/HVJ vaccine exerted a significant prophylactic effect against TB, as indicated by: (1) extension of survival for over a year; (2) improvement of ESR and chest X-ray findings; (3) increase in the body weight;

Please cite this article in press as: Okada M, et al., Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB, Vaccine (2007), doi:10.1016/j.vaccine.2007.01.014

(4) augmentation of immune responses, in a cynomolgus monkey model which closely mimics human TB disease. It is very important to evaluate the long survival period in a monkey model, as human TB is a chronic infection disease. Furthermore, the decrease in the body weight of TB patients is usually accompanied by a progression of the disease [6].

In the guinea pig model, HSP65 + gpIL-12/HVJ provided better protection against the pulmonary pathology caused by pulmonary infection with TB than BCG vaccination (data not shown) (Fig. 3B). In the present study, it was demonstrated that BCG vaccine priming and HSP65 + h IL-12/HVJ booster could provide extremely strong (100% survival) efficacy against *M. tuberculosis* compared to BCG alone (33% survival) in the cynomolgus monkey model. In Japan and other countries, the BCG vaccine is inoculated into human infants (0-6 months after birth). Therefore, BCG priming in infants and HSP65 + h IL-12/HVJ boosters for adults (including junior high school students, high school students and old persons) may be required for the significant improvement of clinical protective efficacy against TB. Our results with the HSP65 + hIL-12/HVJ vaccine in the cynomolgus monkey model should provide a significant rationale for moving this vaccine into clinical trials. Thus, we are taking advantage of the availability of multiple animal models (mouse, guinea pig, and monkey) to accumulate essential data on the HVJ-liposome DNA vaccine in anticipation of a Phase I clinical trial.

Acknowledgements

This study was supported by a Health and Labour Science Research Grant from MHLW (H11-shinko-2, H14-shinko-1, H17-shinko-5), International Collaborative Study Grants from Human Science foundation and Grant-in-Aid for Scientific Research(B) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References

- [1] Yoshida S, Tanaka T, Kita Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against *Mycobacterium tuberculosis* by T cell activation. *Vaccine* 2006;24:1191-204.
- [2] Walsh GP, Tan EV, Dela Cruz EC, et al. The Philippine cynomolgus monkey provides a new nonhuman primate model of tuberculosis that resembles human disease. *Nat Med* 1996;2(4):430-6.
- [3] Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. *Vaccine* 2005;23:2132-5.
- [4] Saeki Y, Matsumoto N, Nakano Y, et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus). *Hum Gene Ther* 1997 Nov 20;8(17):2133-41.
- [5] Okada M, Yoshimura N, Kaieda T, et al. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. *Proc Natl Acad Sci USA* 1981;78(12):7717-21.
- [6] Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001;19:93-129.

小学校低学年児童に発症した喉頭結核を合併した塗沫陽性重症肺結核の一例

A case of progressive pulmonary tuberculosis with laryngeal tuberculosis in a seven-years-old girl

徳永 修 藤本 舟 宮野前 健
国立病院機構南京都病院 小児科
〒610-0113 京都府城陽市中芦原 11

【要旨】

7歳女児に発症した塗沫陽性重症肺結核症の一例を経験した。両側全肺野に経気道性及び血行性両機序により散布された広汎な病巣を認め、喉頭結核の合併も確認された。同居祖父結核発症時の接触者検診の不備、有症状受診例に対する診断の遅れ(“Doctor’s delay”)、問診を中心とした学校結核健診の限界などの要因が重なりあって、本症例の重症化に繋がったものと考えた。

【はじめに】

小児結核症例は近年減少する傾向にあるが、未だ年間 120 例前後の新規発症例が報告されており、更なる小児結核対策の充実が望まれる。集団生活を送る小・中学生においても塗沫陽性肺結核症例は少数例ながら報告されており、その診断の遅れは公衆衛生学上も大きな影響が懸念される。今回、我々は両側全肺野に広がる広汎な病巣を形成した塗沫陽性重症肺結核症の 7 歳女児例を経験した。診断に至るまで長期間にわたって嘔声、咳嗽が持続し喉頭結核の合併も確認された。学童期、特に小学校低学年児童に塗沫陽性肺結核を経験することは極めて稀であり、特に本例のような重症結核症例の報告はこれまでに見られない。症例を報告すると共に重症化に至った本症例の問題点について検討する。

【症例】

〔症例〕7歳女児(小学校1年生)

主訴：発熱、遷延する湿性咳嗽及び嘔声

予防接種歴：生後4ヶ月時、ツベルクリン反応陰性確認後にBCGワクチン接種済み(接種後副反応は認めず)。三種混合、ポリオ、麻疹、風疹、日本脳炎ワクチンもそれぞれ接種済み。

既往歴及び家族歴：4歳時に同居祖父が塗沫陰性肺結核(咳嗽、血痰などの症状が約2ヶ月間持続)を発症した為、管轄保健所において患児に対する接触者検診が実施された。ツベルクリン反応は強陽性(硬結15X13mm/発赤32X28mm、二重発赤あり)であったが、胸部単純写真では発症を示唆する所見を認めなかった。感染源が塗沫陰性であった為、化学予防適応なしと判断され、その後の経過観察も実施されなかった。

現病歴：2004年5月頃より嘔声が出現、近医耳鼻科にて喉頭ファイバー検査を実施され声帯ポリープと診断された。吸入・内服等の治療を受けたが嘔声に改善は見られず、徐々に増悪し入院時まで持続した。同年11月から湿性咳嗽や微熱が持続、近医小児科で加療を続けたが症状は改善しなかった。12月に入って咽頭痛、嚥下困難を伴い、食事摂取量も低下した。2005年1月初めより咳嗽が増強、38℃台の発熱も持続し近医小児科及び耳鼻科での治療を継続した。1月12日近医で実施した血液検査において炎症反応強陽性、高度貧血が判明し前医紹介入院。入院後、経過中初めて撮影された胸部写真にて両側全肺野にびまん性粒状影を認め、喀痰塗沫・PCR検査より結核感染症と診断。1月14日当院に転院となった。

入院時現症：

体温37.5℃、経皮酸素飽和度91%。意識清明、髄膜刺激症状なし。顔色不良で活気なく、眼瞼結膜は貧血様。咽頭発赤を認めたが、扁桃肥大や膿苔付着は見られなかった。胸部聴診上軽度の吸気性狭窄音を聴取するが、ラ音や呼気性狭窄音は認めず、呼吸音減弱も明らかで

なかった。頻呼吸や陥没呼吸などの努力性呼吸パターンも認めなかった。湿性咳嗽が頻発し、高度の嘔声も認めた。頸部及び鎖骨上窩リンパ節腫大や肝脾腫大はなかった。尚、両側上腕にBCG接種痕は確認されなかった。

入院時検査所見（表1）：

血液検査；白血球数の増加、赤沈亢進、CRP強陽性など強い炎症所見を認めた。また、血小板増多、高度の小球性低色素性貧血、低アルブミン血症等の所見も認め、高度の炎症が長期に亘って持続していたことが示唆された。リンパ球表面マーカー検索ではCD4陽性T細胞数の減少、CD4/CD8比の低下を認めた。

髄液検査；細胞増多や蛋白上昇、糖低下など髄膜炎の存在を示唆する所見は認めなかった。細菌学的検査；喀痰抗酸菌染色塗沫陽性(2+;Gaffky5号相当)、PCR(*M. tuberculosis* complex)陽性、抗酸菌培養検査にて結核菌の発育(30コロニー)を認めた。尚、各種抗結核薬に対する薬剤感受性は良好であった。喀痰から病原性一般細菌は検出されなかった。

ツベルクリン反応；発赤・硬結とも全く認めず、anergyと判断した。

入院時画像所見：

胸部単純写真（写真1）；両側全肺野にびまん性に分布する粒状影～小癒合影を認めた。

胸部CT（写真2）；両側上～中肺野を中心に気管支・血管に沿って広がる癒合影、小葉中心性に分布する多数の粒状影～小結節影（周囲に小さな枝を伸ばし“tree in bud”と表現できる陰影も含む）、気管支壁の肥厚を伴った気管支拡張像や小空洞などを認め、経気道散布病巣と判断した。一方、両側下肺野を中心に気道や小葉構造とは無関係にランダムに分布する、比較的サイズの揃ったびまん性小粒状影（径1～3mm程度）を認めた。これらの陰影の一部は血管周囲や胸膜直下に分布しており、血行性に散布した粟粒結核病巣と考えられた。尚、早期播種型粟粒結核症に伴うことが多い縦隔及び肺門部リンパ節腫大は認めなかった。

喉頭ファイバー（写真3）；喉頭蓋から声帯にかけて全周性に発赤を伴い、浮腫状で粗造な粘膜面が確認された。さらに声門下の気管粘膜にも同様な所見が連続して観察され、喉頭結核に合致する所見と判断した。

入院後経過：

胸部画像所見、喉頭ファイバー所見、喀痰検査所見より喉頭結核を合併した塗沫陽性重症肺結核症と診断し抗結核剤4剤（Isoniazid; INH、Rifampicin; RFP、Pyrazinamide; PZA、Streptomycin; SM）による治療を開始した。当初は細菌感染の合併も考慮し抗菌薬（Meropenem）静脈内投与も併用した。入院後3日間は38℃を越える発熱を認めたが、その後は解熱し炎症反応、貧血、低蛋白血症も順次正常化した。湿性咳嗽も徐々に軽減し、治療経過中に強い呼吸苦が出現することはなかった。しかし、治療開始2週後より吸気性喘鳴、嘔声が増強、治療に伴う喉頭病変初期悪化の可能性を考慮し全身性にステロイド投与（Methylprednisolone 2mg/kg/日、以後漸減）を併用した。その後は吸気喘鳴、嘔声ともに軽減した。

入院2週目以降は喀痰塗沫、培養検査共に陰性化、胸部画像所見も徐々に改善傾向を示し（写真4、写真5）、PZA（2ヶ月）、SM（3ヶ月）治療を終え2005年4月退院した。

以後、外来治療を継続し計12ヶ月間のINH、RFP内服治療を終了した。現在、ごく軽度の嘔声は持続しているが、呼吸苦も見られず日常生活に制限を受けることなく元気に学校生活を送っている。呼吸機能検査上中等度の拘束性呼吸障害（%FVC 60%前後）及び末梢気道閉塞性パターン（%V₂₅ 40～50%）を認めている。また、治療終了時に再検したツベルクリン反応は陽性（発赤20mm）、リンパ球表面マーカー検索もそのsubsetに異常を認めなかった。成長曲線では乳児期より平均的な身長発育を認めていたが、5歳6ヶ月頃より成長速度の鈍化（2～3cm/年）が明らかとなり入院時まで持続した。治療開始後は再度良好な身長発育（7cm/年）を認め、徐々にキャッチ・アップしている。

患児を中心とした接触者検診：

患児の姉（13歳）・兄（10歳）・父母、近隣に暮らし頻回に接触のある従弟（7歳）・従妹（5歳、1歳）については当院において家族検診を実施、患児の姉、兄、従妹（1歳）がツ反強